Back to Johnson & Johnson

Johnson & Johnson News

JNJ

J&J EVP Jennifer Taubert to Retire in Sept 2026

Johnson & Johnson EVP Jennifer Taubert to retire Sept 2026. What investors should know about leadership, strategy and near‑term priorities for JNJ.

JNJ

JNJ Completes Firefly Bio Deal; Partners with Sail

Johnson & Johnson (JNJ) finalizes acquisition of Firefly Bio and announces partnership with Sail Biomedicines, reinforcing its Innovative Medicine strategy.

JNJ

J&J Lowers 2026 EPS Midpoint After Firefly Deal

Johnson & Johnson (JNJ) cuts 2026 EPS midpoint by $0.64 following the Firefly Bio acquisition. Investor analysis, risks, and historical context.

JNJ

JNJ Board & DePuy Synthes Leadership Update

Johnson & Johnson (JNJ) appoints John Morikis to the board; Namal Nawana named president of DePuy Synthes. Key investor implications on 2025-10-14.

JNJ

J&J Reports FDA Approvals, AI Launch — JNJ News

J&J (JNJ) wins FDA approvals and launches an AI system on 2025-10-14, advancing oncology and cardiovascular care. Q3 2025 sales $22,471M; watch regulatory/IP risks.

JNJ

J&J Restructures MedTech Operations

Johnson & Johnson (JNJ) begins MedTech restructuring, exiting certain markets and optimizing sites. Investor-focused analysis on financial and strategic implications.

JNJ

JNJ: Namal Nawana Named President of DePuy Synthes

Johnson & Johnson appoints Namal Nawana to lead DePuy Synthes amid its planned Orthopaedics Business separation. (Oct 14, 2025)

JNJ

Johnson & Johnson Q3 2025: Revenue up 6.8%

JNJ Q3 2025: Revenue up 6.8% to $22,471M; Q3 net earnings $5,152M (nearly double). Company raises sales guidance, cites strength in Innovative Medicine and MedTech.

JNJ

J&J to Spin Off DePuy Synthes

Johnson & Johnson (JNJ) plans to separate its Orthopaedics unit as DePuy Synthes. Key investor considerations: MedTech strategy, financials, and execution risks.